Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 481

1.

Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study.

Jongsma HE, Gayer-Anderson C, Lasalvia A, Quattrone D, Mulè A, Szöke A, Selten JP, Turner C, Arango C, Tarricone I, Berardi D, Tortelli A, Llorca PM, de Haan L, Bobes J, Bernardo M, Sanjuán J, Santos JL, Arrojo M, Del-Ben CM, Menezes PR, Murray RM, Rutten BP, Jones PB, van Os J, Morgan C, Kirkbride JB; European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package 2 (EU-GEI WP2) Group.

JAMA Psychiatry. 2017 Dec 6. doi: 10.1001/jamapsychiatry.2017.3554. [Epub ahead of print]

PMID:
29214289
2.

The pathophysiology of human obstructive cholestasis is mimicked in cholestatic Gold Syrian hamsters.

van Golen RF, Olthof PB, de Haan LR, Coelen RJ, Pechlivanis A, de Keijzer MJ, Weijer R, de Waart DR, van Kuilenburg ABP, Roelofsen J, Gilijamse PW, Maas MA, Lewis MR, Nicholson JK, Verheij J, Heger M.

Biochim Biophys Acta. 2017 Nov 28. pii: S0925-4439(17)30444-1. doi: 10.1016/j.bbadis.2017.11.022. [Epub ahead of print]

PMID:
29196240
3.

Satisfaction of psychotic patients with care and its value to predict outcomes.

Vermeulen JM, Schirmbeck NF, van Tricht MJ, de Haan L; Genetic Risk and Outcome of Psychosis (GROUP) investigators.

Eur Psychiatry. 2017 Nov 2;47:60-66. doi: 10.1016/j.eurpsy.2017.10.003. [Epub ahead of print]

PMID:
29102660
4.

The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo.

McHugh MJ, McGorry PD, Yuen HP, Hickie IB, Thompson A, de Haan L, Mossaheb N, Smesny S, Lin A, Markulev C, Schloegelhofer M, Wood SJ, Nieman D, Hartmann JA, Nordentoft M, Schäfer M, Amminger GP, Yung A, Nelson B.

Schizophr Res. 2017 Oct 18. pii: S0920-9964(17)30546-7. doi: 10.1016/j.schres.2017.09.003. [Epub ahead of print]

PMID:
29055567
5.

Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series.

Schipper R, Dekker M, de Haan L, van den Brink W.

J Psychopharmacol. 2017 Oct 1:269881117735684. doi: 10.1177/0269881117735684. [Epub ahead of print]

PMID:
29039260
6.

Memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia.

Veerman S, Schulte P, de Haan L.

Psychopharmacology (Berl). 2017 Dec;234(23-24):3535-3536. doi: 10.1007/s00213-017-4756-9. Epub 2017 Oct 16. No abstract available.

PMID:
29038824
7.

The Relationship Between Clinical and Personal Recovery in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-analysis.

Van Eck RM, Burger TJ, Vellinga A, Schirmbeck F, de Haan L.

Schizophr Bull. 2017 Jul 14. doi: 10.1093/schbul/sbx088. [Epub ahead of print]

PMID:
29036720
8.

The Latent Taxonicity of Schizotypy in Biological Siblings of Probands With Schizophrenia.

Linscott RJ, Morton SE; GROUP (Genetic Risk and Outcome of Psychosis) Investigators.

Schizophr Bull. 2017 Oct 4. doi: 10.1093/schbul/sbx143. [Epub ahead of print]

PMID:
29036385
9.

New Research Strategy for Measuring Pre- and Postnatal Metal Dysregulation in Psychotic Disorders.

Velthorst E, Smith L, Bello G, Austin C, Gennings C, Modabbernia A, Franke N, Frangou S, Wright R, de Haan L, Reichenberg A, Arora M.

Schizophr Bull. 2017 Oct 21;43(6):1153-1157. doi: 10.1093/schbul/sbx112.

PMID:
28981868
10.

Whole genome mRNA transcriptomics analysis reveals different modes of action of the diarrheic shellfish poisons okadaic acid and dinophysis toxin-1 versus azaspiracid-1 in Caco-2 cells.

Bodero M, Hoogenboom RLAP, Bovee TFH, Portier L, de Haan L, Peijnenburg A, Hendriksen PJM.

Toxicol In Vitro. 2018 Feb;46:102-112. doi: 10.1016/j.tiv.2017.09.018. Epub 2017 Sep 20.

11.

Treating depressive episodes or symptoms in patients with schizophrenia.

van Rooijen G, Vermeulen JM, Ruhé HG, de Haan L.

CNS Spectr. 2017 Sep 20:1-10. doi: 10.1017/S1092852917000554. [Epub ahead of print]

PMID:
28927482
12.

Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis.

Hartmann JA, McGorry PD, Schmidt SJ, Amminger GP, Yuen HP, Markulev C, Berger GE, Chen EYH, de Haan L, Hickie IB, Lavoie S, McHugh MJ, Mossaheb N, Nieman DH, Nordentoft M, Riecher-Rössler A, Schäfer MR, Schlögelhofer M, Smesny S, Thompson A, Verma SK, Yung AR, Nelson B.

Psychother Psychosom. 2017;86(5):292-299. doi: 10.1159/000477551. Epub 2017 Sep 14.

PMID:
28903120
13.

An experience sampling study on the ecological validity of the SWN-20: Indication that subjective well-being is associated with momentary affective states above and beyond psychosis susceptibility.

Pos K, de Wit IE, van Dijk FA, Bartels-Velthuis AA, Bruggeman R, Meijer CJ, de Haan L; for Group; Genetic Risk and Outcome of Psychosis investigators, Alizadeh BZ, Bartels-Velthuis AA, Van Beveren NJ, Bruggeman R, Cahn W, de Haan L, Delespaul P, Meijer CJ, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, van Haren NE, van Os J, van Winkel R.

Psychiatry Res. 2017 Dec;258:234-238. doi: 10.1016/j.psychres.2017.08.017. Epub 2017 Aug 18.

PMID:
28851542
14.

A state-independent network of depressive, negative and positive symptoms in male patients with schizophrenia spectrum disorders.

van Rooijen G, Isvoranu AM, Kruijt OH, van Borkulo CD, Meijer CJ, Wigman JTW, Ruhé HG, de Haan L; GROUP investigators.

Schizophr Res. 2017 Aug 22. pii: S0920-9964(17)30446-2. doi: 10.1016/j.schres.2017.07.035. [Epub ahead of print]

PMID:
28844638
15.

Metacognitive training in patients recovering from a first psychosis: an experience sampling study testing treatment effects.

Pos K, Meijer CJ, Verkerk O, Ackema O, Krabbendam L, de Haan L.

Eur Arch Psychiatry Clin Neurosci. 2017 Aug 21. doi: 10.1007/s00406-017-0833-7. [Epub ahead of print]

PMID:
28828697
16.

The Personal Antipsychotic Choice Index.

van Dijk F, de Wit I, Blankers M, Sommer I, de Haan L.

Pharmacopsychiatry. 2017 Aug 15. doi: 10.1055/s-0043-116854. [Epub ahead of print]

PMID:
28810270
17.

Preliminary validation of a clinical staging model in schizophrenia and related disorders.

Tedja A, Velthorst E, van Tricht M, de Haan L; GROUP.

Clin Schizophr Relat Psychoses. 2017 Aug 4. doi: 10.3371/CSRP.ATEV.071317. [Epub ahead of print]

PMID:
28777028
18.

Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Veerman SRT, Schulte PFJ, de Haan L.

Drugs. 2017 Sep;77(13):1423-1459. doi: 10.1007/s40265-017-0789-y. Review.

PMID:
28776162
19.

Familial liability to psychosis is a risk factor for multimorbidity in people with psychotic disorders and their unaffected siblings.

Islam MA, Khan MFH, Quee PJ, Snieder H, van den Heuvel ER, Bruggeman R, Alizadeh BZ; GROUP Investigators.

Eur Psychiatry. 2017 Sep;45:81-89. doi: 10.1016/j.eurpsy.2017.05.001. Epub 2017 Jun 1.

PMID:
28750277
20.

Prenatal developmental toxicity testing of petroleum substances: Application of the mouse embryonic stem cell test (EST) to compare in vitro potencies with potencies observed in vivo.

Kamelia L, Louisse J, de Haan L, Rietjens IMCM, Boogaard PJ.

Toxicol In Vitro. 2017 Oct;44:303-312. doi: 10.1016/j.tiv.2017.07.018. Epub 2017 Jul 23.

Supplemental Content

Loading ...
Support Center